Clinical Approach to Upper Gastrointestinal Bleeding
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of Upper Gastrointestinal Bleeding
Upper gastrointestinal bleeding is a common and potentially life-threatening medical emergency, accounting for approximately 300,000 to 350,000 hospital admissions annually in the United States alone. The incidence ranges from 50 to 150 cases per 100,000 population per year, with mortality rates of 2% to 10% for non-variceal causes and up to 15% to 20% for variceal hemorrhage. Despite advances in endoscopic therapy and critical care, upper gastrointestinal bleeding remains associated with significant morbidity, prolonged hospital stays, and substantial healthcare costs exceeding $2.5 billion annually in the United States.
Definition
Upper gastrointestinal bleeding (UGIB) refers to hemorrhage originating from the gastrointestinal tract proximal to the ligament of Treitz (the suspensory ligament of the duodenum at the duodenojejunal junction). This anatomical landmark divides upper from lower gastrointestinal bleeding and encompasses bleeding from the esophagus, stomach, and duodenum. Clinically, it manifests as hematemesis (vomiting of blood), coffee-ground emesis, melena (black tarry stools), or in cases of massive hemorrhage, hematochezia (bright red blood per rectum).
Classification by Etiology
| Category | Definition | Common Causes | Clinical Significance |
|---|---|---|---|
| Variceal | Bleeding from dilated submucosal veins due to portal hypertension | Esophageal varices, gastric varices, portal hypertensive gastropathy | Higher mortality (15-20%), requires specific management, often recurrent |
| Non-Variceal | All other causes of upper gastrointestinal hemorrhage | Peptic ulcer disease, erosive disease, Mallory-Weiss tears, malignancy | Lower mortality (2-10%), majority of cases, diverse etiologies |
Classification by Severity
| Severity | Blood Loss | Hemodynamic Status | Clinical Features |
|---|---|---|---|
| Mild (Class I) | Less than 15% blood volume (less than 750 mL) | Heart rate less than 100, normal blood pressure | Minimal symptoms, may present with melena alone |
| Moderate (Class II) | 15-30% blood volume (750-1500 mL) | Heart rate 100-120, narrowed pulse pressure | Anxiety, pallor, delayed capillary refill, postural hypotension |
| Severe (Class III) | 30-40% blood volume (1500-2000 mL) | Heart rate 120-140, systolic blood pressure 70-90 mmHg | Confusion, marked pallor, oliguria, tachypnea |
| Massive (Class IV) | Greater than 40% blood volume (greater than 2000 mL) | Heart rate greater than 140, systolic blood pressure less than 70 mmHg | Lethargy, anuria, cold extremities, imminent cardiovascular collapse |
Classification by Clinical Presentation
Hematemesis
Character: Vomiting of fresh red blood or coffee-ground material
Implications: Indicates active or recent bleeding proximal to the ligament of Treitz. Fresh blood suggests rapid, ongoing hemorrhage; coffee-ground appearance indicates blood has been in contact with gastric acid (slower bleed or stopped bleeding).
Melena
Character: Black, tarry, foul-smelling stools
Implications: Requires at least 50-100 mL of blood in the upper gastrointestinal tract. The black color results from degradation of hemoglobin by intestinal bacteria. Can persist for several days after bleeding has stopped.
Coffee-Ground Emesis
Character: Vomitus resembling coffee grounds
Implications: Blood has been oxidized by gastric acid, converting hemoglobin to hematin. Suggests slower bleeding rate or bleeding that has temporarily ceased. Does not exclude significant hemorrhage.
Hematochezia from Upper Source
Character: Bright red blood per rectum despite upper gastrointestinal source
Implications: Indicates massive, rapid upper gastrointestinal bleeding (typically greater than 1000 mL) with accelerated intestinal transit. Associated with hemodynamic instability and high mortality.
Classification by Timing and Acuity
| Category | Definition | Clinical Context |
|---|---|---|
| Acute Overt Bleeding | Recent onset (within hours to days) with visible blood loss | Emergency presentation, requires urgent resuscitation and endoscopy |
| Occult Bleeding | Chronic, slow blood loss without visible hemorrhage | Presents with iron deficiency anemia, positive fecal occult blood test |
| Obscure Bleeding | Recurrent bleeding with negative upper and lower endoscopy | May require capsule endoscopy, deep enteroscopy, or angiography |
| Rebleeding | Recurrence of hemorrhage after initial hemostasis | Occurs in 10-30% of cases, associated with increased mortality |
Key Concept: The “Big Four” Causes of Non-Variceal Upper Gastrointestinal Bleeding
Four conditions account for more than 90% of non-variceal upper gastrointestinal bleeding:
- Peptic Ulcer Disease — 35-50% of all cases (gastric and duodenal ulcers)
- Erosive Disease — 20-30% (gastritis, esophagitis, duodenitis)
- Mallory-Weiss Tears — 5-15% (mucosal lacerations at gastroesophageal junction)
- Esophagogastric Varices — 10-20% (in populations with high cirrhosis prevalence)
Key Epidemiological Facts
- Incidence: 50-150 per 100,000 population annually
- Age: Incidence increases with age; median age 60-70 years
- Sex: Male to female ratio approximately 2:1
- Mortality: Overall 2-10%; in-hospital mortality 6-13%
- Rebleeding rate: 10-30% without endoscopic therapy
- Risk factors: NSAID use, Helicobacter pylori infection, anticoagulation, advanced age, comorbidities
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of Upper Gastrointestinal Bleeding
Understanding the pathophysiology of upper gastrointestinal bleeding is essential for rational diagnostic and therapeutic decision-making. The upper gastrointestinal tract maintains mucosal integrity through a delicate balance between aggressive factors (acid, pepsin, bile, Helicobacter pylori, nonsteroidal anti-inflammatory drugs) and protective factors (mucus-bicarbonate barrier, mucosal blood flow, epithelial regeneration, prostaglandins). Bleeding occurs when this balance is disrupted, leading to mucosal injury, ulceration, or vascular compromise.
Normal Gastric Mucosal Defense
| Defense Layer | Components | Function |
|---|---|---|
| Pre-epithelial | Mucus layer, bicarbonate secretion | Creates pH gradient from lumen (pH 1-2) to epithelial surface (pH 6-7); traps acid and pepsin |
| Epithelial | Tight junctions, cell membrane phospholipids, rapid cell turnover | Physical barrier preventing back-diffusion of hydrogen ions; replacement of damaged cells every 2-4 days |
| Subepithelial | Mucosal blood flow, prostaglandins, growth factors | Delivers oxygen and nutrients, removes toxic metabolites and back-diffused acid; prostaglandins stimulate mucus and bicarbonate secretion |
Pathophysiology of Major Causes
Peptic Ulcer Disease
| Factor | Mechanism of Mucosal Injury | Clinical Implication |
|---|---|---|
| Helicobacter pylori | Urease production creates alkaline microenvironment; cytotoxins (CagA, VacA) cause epithelial damage; inflammatory response disrupts mucosal integrity | Eradication therapy reduces ulcer recurrence from 60-80% to less than 5% |
| Nonsteroidal Anti-Inflammatory Drugs | Inhibit cyclooxygenase-1 (COX-1), reducing prostaglandin synthesis; decreased mucus and bicarbonate secretion; impaired mucosal blood flow; direct topical injury | Risk increases 3-5 fold; discontinuation essential for healing |
| Gastric Acid and Pepsin | Acid denatures proteins; pepsin (activated at pH less than 4) degrades extracellular matrix and disrupts epithelial barrier | Acid suppression with proton pump inhibitors promotes healing and hemostasis |
| Impaired Mucosal Blood Flow | Ischemia from shock, sepsis, or critical illness reduces oxygen delivery and clearance of back-diffused acid | Stress ulcer prophylaxis indicated in critically ill patients |
Mechanism of Bleeding in Peptic Ulcers
Ulcer-Related Bleeding Occurs Through Three Mechanisms:
- Arterial erosion: Deep ulceration erodes into a submucosal or deeper artery (most severe — gastroduodenal artery in posterior duodenal ulcers, left gastric artery in gastric ulcers)
- Venous bleeding: Erosion into submucosal venous plexus (usually slower, often self-limited)
- Diffuse mucosal oozing: Superficial mucosal damage with capillary bleeding (commonly seen in erosive disease)
Esophagogastric Variceal Bleeding
| Pathophysiological Step | Mechanism | Clinical Relevance |
|---|---|---|
| Portal Hypertension | Increased intrahepatic resistance (cirrhosis, fibrosis) and increased splanchnic blood flow lead to portal pressure greater than 10-12 mmHg | Hepatic venous pressure gradient greater than 12 mmHg required for variceal formation |
| Collateral Formation | Porto-systemic collaterals develop at sites of portal-systemic anastomoses; submucosal esophageal and gastric veins dilate | Varices develop in 50% of cirrhotics within 10 years; larger varices have higher bleeding risk |
| Variceal Wall Tension | LaPlace’s law: Wall tension = (Transmural pressure × Radius) / Wall thickness. Large varices with thin walls under high pressure are prone to rupture | Beta-blockers reduce portal pressure; endoscopic banding reduces variceal size |
| Rupture and Hemorrhage | Wall tension exceeds tensile strength; erosion by gastroesophageal reflux may contribute; coagulopathy from liver disease impairs hemostasis | Mortality 15-20% per bleeding episode; 70% rebleed within 1 year without treatment |
Pathophysiology of Other Causes
Mallory-Weiss Tears
Mechanism: Forceful retching or vomiting causes sudden increase in intragastric pressure against a closed glottis, creating longitudinal mucosal lacerations at the gastroesophageal junction.
Location: Typically on the gastric side of the cardia (80-90%)
Natural history: 80-90% stop spontaneously; rarely require intervention
Erosive Esophagitis
Mechanism: Gastroesophageal reflux exposes esophageal squamous epithelium to acid and pepsin; bile reflux may contribute. Epithelium lacks protective mechanisms of gastric mucosa.
Bleeding pattern: Usually chronic, occult blood loss; occasionally severe in deep ulceration
Risk factors: Hiatal hernia, impaired lower esophageal sphincter, delayed gastric emptying
Dieulafoy Lesion
Mechanism: Aberrant submucosal artery (1-3 mm diameter) that fails to branch normally; minimal overlying mucosal defect leads to arterial bleeding without surrounding ulceration.
Location: Proximal stomach (80%), within 6 cm of gastroesophageal junction
Clinical features: Massive, recurrent bleeding; difficult to diagnose when not actively bleeding
Natural Hemostasis and Rebleeding
| Hemostatic Phase | Process | Factors That Impair Hemostasis |
|---|---|---|
| Primary Hemostasis | Vasoconstriction, platelet adhesion and aggregation at injury site, formation of platelet plug | Thrombocytopenia, platelet dysfunction (uremia, aspirin, clopidogrel), von Willebrand disease |
| Secondary Hemostasis | Coagulation cascade activation, fibrin clot formation stabilizing platelet plug | Coagulopathy (liver disease, warfarin), factor deficiencies, direct oral anticoagulants |
| Clot Stabilization | Factor XIII cross-links fibrin; clot retraction; incorporation into vessel wall | Gastric acid (pH less than 6 inhibits platelet aggregation; pH less than 4 lyses clots), pepsin degrades fibrin clots |
Critical Concept: Why Acid Suppression Matters
Platelet aggregation and clot formation are markedly impaired at gastric pH levels below 6. Below pH 4, existing clots undergo dissolution by pepsin-mediated fibrinolysis. High-dose proton pump inhibitor therapy (e.g., intravenous pantoprazole 80 mg bolus followed by 8 mg/hour infusion) maintains intragastric pH above 6, creating an optimal environment for clot stability and reducing rebleeding rates by 40-50% in high-risk ulcers.
Systemic Pathophysiology of Blood Loss
| System | Compensatory Response | Clinical Manifestation |
|---|---|---|
| Cardiovascular | Increased heart rate (catecholamine release), peripheral vasoconstriction (redirects blood to vital organs), increased myocardial contractility | Tachycardia, narrowed pulse pressure, cool extremities, delayed capillary refill |
| Renal | Activation of renin-angiotensin-aldosterone system, antidiuretic hormone release, increased sodium and water retention | Oliguria, elevated blood urea nitrogen (disproportionate to creatinine from absorbed blood proteins) |
| Neurological | Cerebral autoregulation maintains perfusion initially; sympathetic activation | Anxiety, agitation progressing to confusion and lethargy with severe hypovolemia |
| Metabolic | Anaerobic metabolism in hypoperfused tissues | Lactic acidosis, elevated lactate levels indicating tissue hypoperfusion |
Often Overlooked: Azotemia in Upper Gastrointestinal Bleeding
Patients with upper gastrointestinal bleeding frequently develop an elevated blood urea nitrogen (BUN) to creatinine ratio (greater than 30:1). This occurs due to two mechanisms: (1) absorption of blood proteins from the intestinal lumen, which are metabolized to urea, and (2) prerenal azotemia from hypovolemia. This phenomenon helps differentiate upper from lower gastrointestinal bleeding and can be used to monitor ongoing blood loss. The BUN typically normalizes 24-48 hours after bleeding stops.
3. History Taking
A comprehensive approach to eliciting the Upper Gastrointestinal Bleeding history
Red Flags — Require Urgent Evaluation and Resuscitation
- Hematemesis with fresh red blood — Active arterial bleeding, high risk of hemodynamic collapse
- Syncope or near-syncope — Significant blood loss (typically greater than 20% blood volume)
- Ongoing hemodynamic instability — Shock, persistent tachycardia despite resuscitation
- Hematochezia with upper gastrointestinal source — Massive hemorrhage with rapid transit
- Known or suspected variceal bleeding — High mortality, requires specific management
- Anticoagulant use with active bleeding — May require urgent reversal
- Elderly patient (greater than 65 years) with comorbidities — Higher mortality, lower physiological reserve
- Rebleeding after initial endoscopic therapy — Consider surgery or interventional radiology
Systematic History: The “BLEEDING” Approach
Use the mnemonic “BLEEDING” to ensure comprehensive history taking in upper gastrointestinal hemorrhage:
- B — Blood appearance: What did the blood look like? Fresh red, coffee-ground, dark/tarry stools? Volume estimation?
- L — Liver disease: Any history of cirrhosis, hepatitis, alcohol use, or known varices?
- E — Episodes and timing: When did bleeding start? How many episodes? Any previous gastrointestinal bleeding?
- E — Eating and dyspepsia: Recent food intake? History of heartburn, epigastric pain, ulcer disease?
- D — Drugs: NSAIDs, aspirin, anticoagulants, antiplatelet agents, corticosteroids, SSRIs?
- I — Illness and comorbidities: Renal failure, heart disease, coagulopathy, malignancy, recent critical illness?
- N — Nausea, vomiting, retching: Forceful vomiting before hematemesis (Mallory-Weiss)? Weight loss (malignancy)?
- G — General symptoms: Dizziness, weakness, chest pain, shortness of breath, confusion (symptoms of hypovolemia)?
Characterizing the Bleeding Episode
| Question | Clinical Significance | Key Points |
|---|---|---|
| “What did the blood look like?” | Differentiates acuity and location of bleeding | Fresh red = active/rapid bleeding; Coffee-ground = slower bleeding with gastric acid exposure; Black tarry = upper source with intestinal transit |
| “How much blood have you lost?” | Estimates severity (patients often overestimate) | Ask about number of episodes, cups/bowls full; correlate with hemodynamic status rather than patient estimate |
| “When did the bleeding start?” | Acute versus subacute presentation | Acute (hours) suggests arterial/variceal; gradual onset over days may indicate slower venous or erosive bleeding |
| “Have you had bloody or black stools?” | Confirms upper gastrointestinal source | Melena requires minimum 50-100 mL blood in upper gastrointestinal tract; may persist 3-5 days after bleeding stops |
| “Any dizziness when standing?” | Assesses orthostatic symptoms indicating significant blood loss | Postural symptoms suggest greater than 15% blood volume loss; syncope suggests greater than 20% |
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Peptic Ulcer Disease | Epigastric pain, relationship to meals, NSAID use, H. pylori history | “Have you had burning or gnawing pain in your upper abdomen? Does eating make it better or worse? Have you ever been told you have an ulcer or H. pylori infection?” |
| Esophageal Varices | Liver disease, alcohol use, massive painless hematemesis | “Have you ever been told you have liver problems, hepatitis, or cirrhosis? How much alcohol do you drink? Have you had bleeding from varices before?” |
| Mallory-Weiss Tear | Forceful vomiting or retching preceding hematemesis | “Were you vomiting or retching before you saw blood? How many times did you vomit before the blood appeared?” |
| Erosive Esophagitis | Chronic heartburn, regurgitation, dysphagia | “Do you have frequent heartburn or acid reflux? Do you take medications for heartburn? Any difficulty swallowing?” |
| Gastric Malignancy | Weight loss, early satiety, anorexia, dysphagia | “Have you lost weight without trying? Do you feel full quickly after eating? Any family history of stomach cancer?” |
| Aortoenteric Fistula | History of aortic surgery, “herald bleed” followed by massive hemorrhage | “Have you ever had surgery on your aorta or a stent placed in your aorta? Any recent smaller bleeding episodes?” |
| Dieulafoy Lesion | Recurrent massive bleeding, no ulcer symptoms, prior negative endoscopies | “Have you had previous episodes of massive bleeding where they couldn’t find the source? Any prior endoscopies that were normal?” |
Medication and Social History
Medications That Increase Bleeding Risk
- Nonsteroidal anti-inflammatory drugs (NSAIDs): Directly damage mucosa, inhibit prostaglandin protection; 3-5× increased ulcer risk
- Aspirin (including low-dose): Irreversible platelet inhibition; even 75-100 mg daily doubles bleeding risk
- Anticoagulants (warfarin, direct oral anticoagulants): Impair clot formation; may unmask occult lesions
- Dual antiplatelet therapy (aspirin + clopidogrel): Synergistic bleeding risk; 7× increased risk
- Corticosteroids: Increase risk when combined with NSAIDs; impair mucosal healing
- Selective serotonin reuptake inhibitors (SSRIs): Impair platelet serotonin uptake; 2× risk when combined with NSAIDs
- Bisphosphonates: Can cause erosive esophagitis if not taken properly
Social and Past Medical History
- Alcohol use: Quantify intake; assess for liver disease, varices, gastritis; recent binge (Mallory-Weiss)
- Smoking: Impairs ulcer healing, increases recurrence; associated with gastric cancer
- Previous gastrointestinal bleeding: Recurrent bleeding suggests inadequately treated underlying cause
- Prior endoscopy findings: Known ulcers, varices, Barrett’s esophagus, angiodysplasia
- Liver disease: Cirrhosis, hepatitis B or C, fatty liver disease
- Renal disease: Uremic platelet dysfunction; increased bleeding risk
- Cardiac disease: May not tolerate blood loss; risk of demand ischemia
- Recent critical illness: Stress ulceration risk in intensive care setting
Ask About Helicobacter pylori Status
Helicobacter pylori infection is present in 70-90% of duodenal ulcers and 60-80% of gastric ulcers. Key questions include:
- “Have you ever been tested for Helicobacter pylori (the bacteria that causes ulcers)?”
- “Have you ever taken antibiotics for an ulcer or stomach infection?”
- “Did you complete the full course of treatment?”
- “Were you retested after treatment to confirm the infection was cleared?”
Many patients with recurrent bleeding have either untreated infection or failed eradication therapy.
4. Physical Examination
A systematic approach for Upper Gastrointestinal Bleeding
Systematic Framework: In acute upper gastrointestinal bleeding, the primary goal of physical examination is to assess hemodynamic status and identify stigmata of underlying disease. Use the “ABC-FAST-STIGMATA” approach: Airway, Breathing, Circulation first, then Focused Assessment for Severity and Targeted examination for Stigmata of underlying etiology.
Initial Hemodynamic Assessment (First 60 Seconds)
- Level of consciousness: Alert versus confused versus obtunded (reflects cerebral perfusion)
- Skin color and temperature: Pallor, diaphoresis, cool extremities (peripheral vasoconstriction)
- Respiratory effort: Tachypnea may indicate acidosis or compensation for anemia
- Visible blood: Blood on lips, clothing, emesis basin; actively vomiting blood
- General distress: Patient appearance — calm versus anxious versus moribund
Vital Signs and Their Interpretation
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Heart Rate | Tachycardia (greater than 100 beats per minute); resting heart rate greater than 100 is concerning | Compensatory response to hypovolemia; may be blunted by beta-blockers; persistent tachycardia indicates ongoing bleeding or inadequate resuscitation |
| Blood Pressure | Hypotension (systolic less than 90 mmHg); narrowed pulse pressure | Hypotension indicates greater than 30% blood volume loss; earlier sign is narrowed pulse pressure (systolic minus diastolic less than 25 mmHg) |
| Orthostatic Vital Signs | Increase in heart rate greater than 20 beats per minute or decrease in systolic blood pressure greater than 20 mmHg upon standing | Positive orthostatic changes suggest 15-20% blood volume loss; perform only if patient is stable enough to stand safely |
| Respiratory Rate | Tachypnea (greater than 20 breaths per minute) | May indicate metabolic acidosis from hypoperfusion or respiratory compensation for anemia |
| Oxygen Saturation | May be normal despite significant anemia | Pulse oximetry measures saturation, not oxygen content; can be falsely reassuring in severe anemia with good saturation but low hemoglobin |
| Temperature | Fever or hypothermia | Fever may indicate infection (spontaneous bacterial peritonitis in cirrhosis, aspiration); hypothermia in severe shock |
Shock Index: A Quick Bedside Tool
Shock Index = Heart Rate ÷ Systolic Blood Pressure
- Normal: 0.5-0.7
- Greater than 0.9: Suggests significant hemorrhage requiring aggressive resuscitation
- Greater than 1.0: Associated with increased mortality; consider blood transfusion and urgent intervention
The shock index is more sensitive than heart rate or blood pressure alone for detecting early hypovolemia.
Head and Neck Examination
Eyes
- Conjunctival pallor: Examine lower palpebral conjunctiva — pale color suggests hemoglobin less than 9 g/dL
- Scleral icterus: Yellow discoloration indicates hyperbilirubinemia (liver disease)
- Kayser-Fleischer rings: Rare; suggests Wilson disease with hepatic involvement
Mouth and Oropharynx
- Blood in mouth or nasogastric aspirate: Confirms upper gastrointestinal source
- Mucosal pallor: Examine under the tongue and buccal mucosa
- Fetor hepaticus: Sweet, musty breath odor in hepatic encephalopathy
- Poor dentition: May indicate poor nutrition, alcohol use
Stigmata of Chronic Liver Disease
| Finding | Description | Clinical Significance |
|---|---|---|
| Jaundice | Yellow discoloration of skin and sclerae | Bilirubin greater than 2.5-3 mg/dL; indicates hepatic dysfunction |
| Spider angiomata | Central arteriole with radiating vessels; blanches with pressure; upper body distribution | More than 3 spider angiomata strongly suggests cirrhosis; related to elevated estrogen |
| Palmar erythema | Reddening of thenar and hypothenar eminences | Seen in cirrhosis; also pregnancy, rheumatoid arthritis, thyrotoxicosis |
| Gynecomastia | Breast tissue enlargement in males | Altered estrogen-testosterone ratio in cirrhosis |
| Testicular atrophy | Small, soft testes | Hypogonadism in chronic liver disease |
| Caput medusae | Dilated periumbilical veins radiating from umbilicus | Portal hypertension with recanalization of umbilical vein; uncommon but specific |
| Ascites | Abdominal distension, shifting dullness, fluid wave | Portal hypertension; increases variceal bleeding risk; may harbor spontaneous bacterial peritonitis |
| Asterixis | Flapping tremor of dorsiflexed wrists | Hepatic encephalopathy; indicates significant hepatic dysfunction |
| Dupuytren contracture | Thickening and contracture of palmar fascia | Associated with alcoholic liver disease |
Abdominal Examination
Inspection
- Distension: Ascites (fluid wave, shifting dullness), obesity, bowel obstruction
- Surgical scars: Prior abdominal aortic aneurysm repair (aortoenteric fistula risk), prior gastrointestinal surgery
- Caput medusae: Dilated periumbilical veins
- Visible peristalsis: May indicate obstruction
Palpation
- Epigastric tenderness: Peptic ulcer disease, gastritis
- Hepatomegaly: Liver edge more than 2 cm below right costal margin; may be tender in acute hepatitis or congestion
- Splenomegaly: Palpable spleen suggests portal hypertension (normally not palpable)
- Masses: Epigastric mass may indicate gastric malignancy
- Peritoneal signs: Guarding, rigidity, rebound — suggests perforation (rare but critical)
Percussion
- Shifting dullness: Indicates ascites (greater than 1500 mL needed for detection)
- Liver span: Normal 6-12 cm in midclavicular line; enlarged in early cirrhosis, shrunken in advanced cirrhosis
- Splenic dullness: Traube’s space dullness suggests splenomegaly
Auscultation
- Hyperactive bowel sounds: Blood in gastrointestinal tract is cathartic; increased bowel sounds common
- Venous hum: Continuous hum over epigastrium; rarely heard with extensive portosystemic collaterals
Rectal Examination
Essential Component of Evaluation
Digital rectal examination is mandatory in suspected gastrointestinal bleeding:
- Stool color: Melena (black, tarry, foul-smelling) confirms upper source; maroon stool suggests brisk upper or lower bleeding; bright red blood may indicate massive upper gastrointestinal bleeding or lower source
- Occult blood testing: Guaiac testing if stool appears normal
- Hemorrhoids: May be source of bright red blood, but do not assume — must exclude upper source
- Rectal masses: May indicate malignancy
- Prostatic abnormalities: Incidental finding, not related to bleeding
Cardiovascular Examination
- Capillary refill: Delayed (greater than 3 seconds) indicates peripheral vasoconstriction and hypovolemia
- Peripheral pulses: Weak, thready pulses suggest significant volume loss
- Jugular venous pressure: Low in hypovolemia; elevated may suggest cardiac comorbidity or fluid overload after resuscitation
- Heart sounds: Systolic flow murmur common in severe anemia; new murmur may indicate underlying cardiac disease
- Peripheral edema: May indicate chronic liver disease, heart failure, or hypoalbuminemia
Expected Findings by Etiology
| Condition | General Appearance | Abdominal Findings | Other Key Findings |
|---|---|---|---|
| Peptic Ulcer Disease | Variable; may appear well or shocked depending on severity | Epigastric tenderness; otherwise often unremarkable | May have no specific findings; peritonitis if perforated |
| Variceal Bleeding | Often cachectic; may have chronic illness appearance | Hepatosplenomegaly, ascites, caput medusae | Spider angiomata, jaundice, palmar erythema, gynecomastia, asterixis |
| Mallory-Weiss Tear | May appear well between episodes of vomiting | Usually non-tender or mild epigastric tenderness | May have signs of alcohol intoxication or recent illness causing vomiting |
| Gastric Malignancy | Cachexia, weight loss, pallor | Epigastric mass (late finding), hepatomegaly with metastases | Virchow node (left supraclavicular), Sister Mary Joseph nodule (periumbilical) |
| Erosive Gastritis/Esophagitis | Variable; often mild presentation | Usually unremarkable; mild epigastric tenderness | May have no specific examination findings |
| Aortoenteric Fistula | May be stable initially (herald bleed) then catastrophic | Abdominal aortic aneurysm repair scar; may have pulsatile mass | High index of suspicion needed; often no specific findings until massive hemorrhage |
Critical Teaching Point: Physical Examination Limitations
Normal vital signs do not exclude significant bleeding!
- Young, healthy patients may maintain normal blood pressure until greater than 30% blood volume is lost
- Beta-blocker therapy masks tachycardia — heart rate may remain normal despite hypovolemia
- Initial hemoglobin may be normal due to hemoconcentration — it takes 24-72 hours to equilibrate
- Elderly patients may have baseline hypertension — “normal” blood pressure of 100/60 may represent significant hypotension
- Patients on anticoagulants may have ongoing bleeding despite minimal initial presentation
Always correlate examination findings with clinical context, laboratory values, and hemodynamic trends over time.
5. Differential Diagnosis
Systematic approach organized by probability and clinical features
The differential diagnosis of upper gastrointestinal bleeding is broad, but a systematic approach based on probability, clinical presentation, and patient risk factors allows efficient narrowing of possibilities. The key initial distinction is between variceal and non-variceal sources, as management differs significantly.
Non-Variceal Upper Gastrointestinal Bleeding (80-90% of cases)
| Probability | Condition | Frequency | Key Features | Red Flags |
|---|---|---|---|---|
| COMMON | Peptic Ulcer Disease (Gastric and Duodenal Ulcers) | 35-50% | Epigastric pain, NSAID or aspirin use, Helicobacter pylori infection, prior ulcer history | Posterior duodenal ulcer (gastroduodenal artery erosion), lesser curve gastric ulcer (left gastric artery) |
| COMMON | Erosive Gastritis and Duodenitis | 20-30% | NSAID use, alcohol, critical illness (stress ulceration), diffuse mucosal injury | Multiple erosions may cause significant cumulative blood loss |
| COMMON | Erosive Esophagitis | 10-15% | Chronic heartburn, dysphagia, hiatal hernia, obesity | Severe (Los Angeles Grade C/D) erosions; Barrett’s esophagus with ulceration |
| COMMON | Mallory-Weiss Tear | 5-15% | Forceful vomiting or retching preceding hematemesis, alcohol use, hyperemesis | Usually self-limited; rarely requires intervention |
| LESS COMMON | Gastric or Esophageal Malignancy | 2-5% | Weight loss, anorexia, early satiety, dysphagia, older age, family history | Advanced disease often presents with bleeding; Virchow node, Sister Mary Joseph nodule |
| LESS COMMON | Angiodysplasia (Arteriovenous Malformations) | 2-5% | Elderly patients, chronic kidney disease, aortic stenosis (Heyde syndrome), recurrent bleeding | Often occult or intermittent; may be multiple lesions |
| LESS COMMON | Dieulafoy Lesion | 1-2% | Massive, recurrent bleeding; minimal or no ulcer; proximal stomach; often elderly males | Difficult to diagnose when not actively bleeding; high rebleeding rate |
| UNCOMMON BUT SERIOUS | Aortoenteric Fistula | Less than 1% | Prior aortic surgery or endovascular repair, “herald bleed” followed by massive hemorrhage | High mortality; requires high index of suspicion; emergent surgical consultation |
| UNCOMMON BUT SERIOUS | Hemobilia | Less than 1% | Recent hepatobiliary procedure, trauma, hepatic artery aneurysm; classic triad: biliary colic, jaundice, gastrointestinal bleeding | May require angiography for diagnosis and treatment |
| UNCOMMON BUT SERIOUS | Hemosuccus Pancreaticus | Rare | Chronic pancreatitis, pseudocyst, splenic artery pseudoaneurysm; bleeding through pancreatic duct | Intermittent bleeding; may require CT angiography for diagnosis |
Variceal Upper Gastrointestinal Bleeding (10-20% of cases)
Key Principle: Variceal bleeding should be suspected in any patient with known or suspected liver disease, portal hypertension, or stigmata of chronic liver disease. The management differs significantly from non-variceal bleeding, including specific pharmacotherapy (vasoactive agents) and endoscopic techniques (band ligation).
| Probability | Condition | Key Features | Clinical Significance |
|---|---|---|---|
| MOST COMMON | Esophageal Varices | Cirrhosis, portal hypertension, massive painless hematemesis, stigmata of liver disease | 15-20% mortality per episode; 70% rebleed within 1 year without secondary prophylaxis |
| LESS COMMON | Gastric Varices | Often associated with splenic vein thrombosis; may occur without esophageal varices (isolated gastric varices) | More difficult to treat endoscopically; may require cyanoacrylate injection or TIPS |
| LESS COMMON | Portal Hypertensive Gastropathy | Mosaic or snakeskin pattern of gastric mucosa; usually chronic occult blood loss | Rarely causes acute severe bleeding; treat underlying portal hypertension |
| UNCOMMON | Gastric Antral Vascular Ectasia (Watermelon Stomach) | Red stripes radiating from pylorus; associated with cirrhosis, autoimmune conditions, chronic kidney disease | Usually chronic blood loss; may require endoscopic ablation |
| UNCOMMON | Ectopic Varices | Varices at unusual sites: duodenum, jejunum, stomal sites; prior abdominal surgery | Difficult to diagnose; may require specialized imaging or enteroscopy |
Anatomical Approach to Differential Diagnosis
Esophagus
Esophageal varices
Erosive esophagitis
Esophageal ulcer
Esophageal malignancy
Mallory-Weiss tear (esophageal side)
Boerhaave syndrome (rare)
Gastroesophageal Junction
Mallory-Weiss tear (most common location)
Gastric cardia varices
Cameron lesions (hiatal hernia erosions)
Junctional malignancy
Stomach
Gastric ulcer
Erosive gastritis
Gastric varices
Gastric malignancy
Dieulafoy lesion
Portal hypertensive gastropathy
Gastric antral vascular ectasia
Angiodysplasia
Duodenum
Duodenal ulcer
Erosive duodenitis
Duodenal varices
Aortoenteric fistula
Hemobilia (bleeding through ampulla)
Hemosuccus pancreaticus
Duodenal malignancy (rare)
Drug-Induced Upper Gastrointestinal Bleeding
| Drug or Drug Class | Mechanism | Risk Level | Management Considerations |
|---|---|---|---|
| Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | COX-1 inhibition reduces prostaglandin-mediated mucosal protection; direct topical injury | 3-5× increased risk; 15× with high-dose or multiple NSAIDs | Discontinue; consider COX-2 selective agent with proton pump inhibitor if NSAID essential |
| Aspirin (all doses) | Irreversible COX-1 inhibition; impaired platelet aggregation | 2-4× increased risk; even 75 mg daily significant | Weigh cardiovascular benefit against bleeding risk; consider proton pump inhibitor co-prescription |
| Warfarin | Vitamin K antagonist; impairs clotting factor synthesis | 2-4× increased risk; higher with supratherapeutic INR | Reversal with vitamin K, prothrombin complex concentrate, or fresh frozen plasma; reassess anticoagulation indication |
| Direct Oral Anticoagulants (DOACs) | Direct thrombin or Factor Xa inhibition | Similar or slightly lower than warfarin for gastrointestinal bleeding | Specific reversal agents available (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors) |
| Clopidogrel and P2Y12 Inhibitors | Irreversible platelet ADP receptor blockade | 1.5-2× increased risk; synergistic with aspirin (7× risk) | Platelet transfusion may be needed; discuss with cardiology if recent coronary stent |
| Corticosteroids | Impaired mucosal healing; increased risk when combined with NSAIDs (15× risk) | Minimal independent risk; significant when combined with NSAIDs | Avoid NSAID combination; consider proton pump inhibitor prophylaxis if high-dose steroids |
| Selective Serotonin Reuptake Inhibitors (SSRIs) | Impair platelet serotonin uptake and aggregation | 2× increased risk; higher when combined with NSAIDs | Consider proton pump inhibitor co-prescription in high-risk patients |
| Bisphosphonates | Direct mucosal irritation causing erosive esophagitis | Risk with improper administration (not taken upright, insufficient water) | Review administration technique; consider IV formulation if severe esophagitis |
| Potassium Chloride (oral) | Direct mucosal injury, especially if tablet lodges in esophagus | Risk with large tablets, strictures, dysmotility | Use liquid formulation; ensure adequate fluid intake |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| NSAID use + epigastric pain + hematemesis | Peptic ulcer disease | Stop NSAIDs, proton pump inhibitor, urgent endoscopy |
| Known cirrhosis + massive hematemesis | Esophageal or gastric varices | Vasoactive therapy (octreotide/terlipressin), antibiotics, urgent endoscopy with banding |
| Forceful vomiting then hematemesis | Mallory-Weiss tear | Usually self-limited; endoscopy if ongoing bleeding or hemodynamic instability |
| Weight loss + early satiety + bleeding | Gastric malignancy | Urgent endoscopy with biopsy; staging if confirmed |
| Prior aortic surgery + gastrointestinal bleeding | Aortoenteric fistula | CT angiography; emergent vascular surgery consultation |
| Chronic kidney disease + recurrent bleeding + no ulcer | Angiodysplasia | Consider Heyde syndrome (aortic stenosis); may need repeat endoscopy or capsule endoscopy |
| Massive bleeding + proximal stomach + no ulcer visible | Dieulafoy lesion | Careful examination of gastric fundus during active bleeding; endoscopic therapy |
| Recent liver biopsy or ERCP + gastrointestinal bleeding + jaundice | Hemobilia | CT angiography; hepatic artery embolization may be needed |
| Chronic pancreatitis + intermittent bleeding | Hemosuccus pancreaticus | CT angiography to evaluate for splenic artery pseudoaneurysm |
| Elderly + aortic stenosis + occult blood loss | Heyde syndrome (angiodysplasia with acquired von Willebrand syndrome) | Echocardiography; consider aortic valve replacement which may resolve bleeding |
Differential Diagnosis by Presentation Pattern
Acute Massive Hemorrhage
Hemodynamic instability, large volume hematemesis or hematochezia
- Peptic ulcer with arterial erosion
- Esophageal or gastric variceal rupture
- Dieulafoy lesion
- Aortoenteric fistula
- Malignancy with vessel erosion
Chronic Occult Blood Loss
Iron deficiency anemia, positive fecal occult blood test, no overt bleeding
- Cameron lesions (hiatal hernia)
- Angiodysplasia
- Portal hypertensive gastropathy
- Gastric antral vascular ectasia
- Erosive esophagitis
- Occult malignancy
6. Diagnostic Investigations
A stepwise, goal-directed approach to evaluation and risk stratification
The investigation of upper gastrointestinal bleeding serves three main purposes: (1) assessing severity and guiding resuscitation, (2) risk stratification to determine timing and setting of endoscopy, and (3) identifying the source and guiding definitive therapy. A systematic approach ensures efficient use of resources while avoiding diagnostic delays.
Immediate Investigations (Within 60 Minutes of Presentation)
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Complete Blood Count | Assess hemoglobin, hematocrit, platelet count | Hemoglobin (may be normal initially); thrombocytopenia (liver disease, bone marrow suppression) | Initial hemoglobin does not reflect acute blood loss; takes 24-72 hours to equilibrate; serial measurements essential |
| Blood Type and Crossmatch | Prepare for transfusion | Blood group, antibody screen | Crossmatch at least 2-4 units initially; more if massive bleeding or high-risk patient |
| Coagulation Studies (PT/INR, aPTT) | Assess coagulopathy, anticoagulant effect | Elevated INR (warfarin, liver disease); prolonged aPTT (heparin, intrinsic pathway defects) | Guide reversal therapy; INR greater than 1.5 associated with increased bleeding risk |
| Basic Metabolic Panel | Assess renal function, electrolytes | Elevated BUN (blood protein absorption, prerenal azotemia); creatinine; electrolyte abnormalities | BUN:creatinine ratio greater than 30:1 suggests upper gastrointestinal source; guide fluid resuscitation |
| Liver Function Tests | Assess for liver disease, guide variceal suspicion | Elevated bilirubin, low albumin, elevated transaminases; synthetic dysfunction suggests cirrhosis | Low albumin indicates chronic liver disease; guides suspicion for variceal bleeding |
| Lactate | Assess tissue perfusion | Elevated lactate indicates hypoperfusion and shock | Greater than 4 mmol/L associated with high mortality; guide resuscitation adequacy |
| Arterial Blood Gas (if indicated) | Assess acid-base status, oxygenation in severe cases | Metabolic acidosis (hypoperfusion); respiratory compensation | Reserve for hemodynamically unstable patients or those with respiratory compromise |
| ECG | Assess for cardiac ischemia from anemia | ST changes, arrhythmias indicating demand ischemia | Essential in patients with known cardiac disease or chest pain; anemia can precipitate ischemia |
Clinical Pearl: BUN:Creatinine Ratio
An elevated BUN:creatinine ratio (greater than 30:1) in a patient with gastrointestinal bleeding strongly suggests an upper gastrointestinal source. This occurs due to:
- Absorption of blood proteins: Blood in the intestinal lumen is digested, and amino acids are absorbed and converted to urea in the liver
- Prerenal azotemia: Hypovolemia from blood loss reduces renal perfusion
This ratio can help differentiate upper from lower gastrointestinal bleeding when the source is unclear (e.g., patient presenting with melena or hematochezia).
Risk Stratification Scores
Glasgow-Blatchford Score (Pre-Endoscopic)
| Parameter | Finding | Points |
|---|---|---|
| Blood Urea Nitrogen | 18.2-22.4 mg/dL (6.5-8.0 mmol/L) | 2 |
| 22.4-28.0 mg/dL (8.0-10.0 mmol/L) | 3 | |
| 28.0-70.0 mg/dL (10.0-25.0 mmol/L) | 4 | |
| Greater than 70.0 mg/dL (greater than 25.0 mmol/L) | 6 | |
| Hemoglobin (males) | 12.0-13.0 g/dL | 1 |
| 10.0-12.0 g/dL | 3 | |
| Less than 10.0 g/dL | 6 | |
| Hemoglobin (females) | 10.0-12.0 g/dL | 1 |
| Less than 10.0 g/dL | 6 | |
| Systolic Blood Pressure | 100-109 mmHg | 1 |
| 90-99 mmHg | 2 | |
| Less than 90 mmHg | 3 | |
| Heart Rate | Greater than or equal to 100 beats per minute | 1 |
| Melena | Present | 1 |
| Syncope | Present | 2 |
| Hepatic Disease | Present | 2 |
| Heart Failure | Present | 2 |
Glasgow-Blatchford Score Interpretation:
- Score 0-1: Very low risk; may be suitable for outpatient management with early outpatient endoscopy
- Score 2-11: Intermediate risk; requires hospital admission and endoscopy within 24 hours
- Score greater than or equal to 12: High risk; consider intensive care admission, urgent endoscopy within 12 hours
Rockall Score (Post-Endoscopic)
| Variable | 0 Points | 1 Point | 2 Points | 3 Points |
|---|---|---|---|---|
| Age | Less than 60 years | 60-79 years | Greater than or equal to 80 years | — |
| Shock | None (SBP greater than 100, HR less than 100) | Tachycardia (HR greater than 100, SBP greater than 100) | Hypotension (SBP less than 100) | — |
| Comorbidity | None | — | Heart failure, ischemic heart disease, major morbidity | Renal failure, liver failure, metastatic cancer |
| Diagnosis | Mallory-Weiss, no lesion, no stigmata | All other diagnoses | Gastrointestinal malignancy | — |
| Stigmata of Recent Hemorrhage | None or dark spot | — | Blood in upper GI tract, adherent clot, visible vessel, active bleeding | — |
Rockall Score Interpretation
- Score 0-2: Low risk (rebleeding less than 5%, mortality less than 0.1%)
- Score 3-4: Intermediate risk (rebleeding 10-15%, mortality 3-5%)
- Score 5-7: High risk (rebleeding 25-40%, mortality 15-25%)
- Score greater than or equal to 8: Very high risk (rebleeding greater than 40%, mortality greater than 40%)
Esophagogastroduodenoscopy (EGD): The Cornerstone Investigation
| Aspect | Details |
|---|---|
| Timing | Within 24 hours for most patients; within 12 hours for high-risk patients (hemodynamic instability, suspected variceal bleeding, high Glasgow-Blatchford score); emergent (within 2 hours) for massive ongoing bleeding unresponsive to resuscitation |
| Diagnostic Yield | Identifies source in 90-95% of cases; higher when performed early (within 24 hours) |
| Therapeutic Capability | Allows immediate treatment: injection therapy (epinephrine, sclerosant), thermal coagulation (heater probe, argon plasma coagulation), mechanical therapy (clips, bands) |
| Prognostic Information | Forrest classification for ulcers predicts rebleeding risk; guides intensity of monitoring and repeat intervention |
| Pre-Endoscopy Preparation | Consider erythromycin (250 mg IV 30-120 minutes before) as prokinetic to clear gastric contents and improve visualization; airway protection (intubation) if altered mental status or massive hematemesis |
Forrest Classification of Peptic Ulcer Bleeding
| Classification | Endoscopic Appearance | Rebleeding Risk | Management |
|---|---|---|---|
| Forrest Ia | Spurting arterial hemorrhage | 90% | Endoscopic therapy mandatory; consider surgery if fails |
| Forrest Ib | Oozing hemorrhage | 50% | Endoscopic therapy recommended |
| Forrest IIa | Non-bleeding visible vessel | 40-50% | Endoscopic therapy recommended |
| Forrest IIb | Adherent clot | 20-30% | Consider clot removal and treatment of underlying lesion |
| Forrest IIc | Flat pigmented spot (hematin) | 5-10% | No endoscopic therapy needed; medical management |
| Forrest III | Clean ulcer base | Less than 5% | No endoscopic therapy needed; may consider early discharge |
Targeted Investigations by Suspected Etiology
If Suspecting Variceal Bleeding
Pre-Endoscopy Investigations
- Liver function tests: Assess synthetic function (albumin, INR), cholestasis (bilirubin, alkaline phosphatase)
- Complete metabolic panel: Renal function, electrolytes (hyponatremia in cirrhosis)
- Platelet count: Thrombocytopenia common in cirrhosis (splenic sequestration)
- Blood cultures: Infections common in cirrhotic patients; spontaneous bacterial peritonitis
Additional Considerations
- MELD score calculation: Model for End-Stage Liver Disease; predicts mortality
- Child-Pugh score: Assesses severity of liver disease
- Abdominal ultrasound with Doppler: Assess liver size, splenomegaly, ascites, portal vein patency
- Diagnostic paracentesis: If ascites present, rule out spontaneous bacterial peritonitis
If Suspecting Aortoenteric Fistula
Imaging Studies
- CT angiography: First-line imaging; look for perigraft air, fluid, contrast extravasation, loss of fat plane between graft and duodenum
- CT with oral contrast: May show contrast in bowel lumen from fistula
Key Points
- Do not delay: Mortality approaches 100% without surgery
- EGD may show: Graft erosion into duodenum (usually third or fourth portion)
- Negative CT does not exclude: High clinical suspicion warrants surgical exploration
If Endoscopy is Non-Diagnostic
| Clinical Scenario | Next Investigation | Purpose |
|---|---|---|
| Ongoing bleeding, non-diagnostic EGD | CT angiography or conventional angiography | Detect active bleeding (requires bleeding rate greater than 0.5-1 mL/min for CT, greater than 0.5 mL/min for angiography) |
| Recurrent bleeding, negative EGD and colonoscopy | Capsule endoscopy | Evaluate small bowel for angiodysplasia, tumors, ulcers |
| Small bowel source suspected | Push enteroscopy or deep balloon enteroscopy | Diagnostic and therapeutic access to small bowel |
| Intermittent bleeding, prior negative workup | Tagged red blood cell scan | Detects slower bleeding (0.1-0.4 mL/min); helps localize for subsequent angiography or surgery |
| Suspected hemobilia or hemosuccus pancreaticus | CT angiography or MR angiography | Evaluate hepatic or splenic artery pseudoaneurysm |
Helicobacter pylori Testing
Testing in the Context of Acute Bleeding
All patients with peptic ulcer bleeding should be tested for Helicobacter pylori infection:
- Rapid urease test (biopsy-based): Can be performed during endoscopy; sensitivity reduced in acute bleeding (false negatives due to blood in stomach)
- Histology: Obtained during endoscopy; gold standard but results delayed
- Stool antigen test: Non-invasive; useful if endoscopic tests negative or not performed
- Urea breath test: Accurate but impractical in acute setting
- Serology: Does not distinguish active from past infection; useful if other tests negative and suspicion high
Important: If initial testing is negative but clinical suspicion remains high, retest 4-8 weeks later after proton pump inhibitor discontinuation (PPIs reduce sensitivity of all tests except serology).
Investigation Algorithm Summary
Stepwise Approach to Investigation:
- Immediate (0-60 minutes): CBC, type and crossmatch, coagulation studies, metabolic panel, liver function tests, lactate, ECG
- Risk stratify: Calculate Glasgow-Blatchford score to guide disposition and endoscopy timing
- Resuscitate: Guide by hemodynamic response, serial hemoglobin, and lactate clearance
- Endoscopy: Within 24 hours for most; within 12 hours for high-risk; emergent for massive bleeding
- Post-endoscopy: Calculate Rockall score; test for Helicobacter pylori if peptic ulcer
- If non-diagnostic: CT angiography, capsule endoscopy, or angiography based on clinical scenario
7. Clinical Decision-Making
Practical algorithms and decision pathways for Upper Gastrointestinal Bleeding
Step 1: Is This Urgent? Initial Triage
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Massive hematemesis with hemodynamic instability (systolic blood pressure less than 90 mmHg, heart rate greater than 120) | EMERGENT | Two large-bore IVs, activate massive transfusion protocol, call gastroenterology and surgery immediately, consider intubation for airway protection, emergent endoscopy once resuscitated |
| Known or suspected variceal bleeding | EMERGENT | Start octreotide (50 mcg bolus then 50 mcg/hour) or terlipressin, prophylactic antibiotics (ceftriaxone 1g IV), restrictive transfusion, urgent endoscopy within 12 hours |
| Suspected aortoenteric fistula (prior aortic surgery + gastrointestinal bleeding) | EMERGENT | Emergent CT angiography, vascular surgery consultation immediately, prepare for emergent operation |
| Hematemesis or melena with tachycardia but stable blood pressure | URGENT | IV access, fluid resuscitation, type and crossmatch, proton pump inhibitor infusion, admit to monitored bed, endoscopy within 24 hours |
| Coffee-ground emesis, hemodynamically stable, no high-risk features | URGENT | IV proton pump inhibitor, admit for observation, endoscopy within 24 hours |
| Melena alone, hemodynamically stable, low Glasgow-Blatchford score (0-1) | LESS URGENT | Consider outpatient management with early outpatient endoscopy if reliable patient with good social support; otherwise admit for observation |
Step 2: Resuscitation Goals and Transfusion Thresholds
| Parameter | Target | Rationale |
|---|---|---|
| Hemoglobin transfusion threshold (most patients) | Transfuse if hemoglobin less than 7 g/dL; target 7-9 g/dL | Restrictive strategy reduces mortality, rebleeding, and complications compared to liberal transfusion |
| Hemoglobin transfusion threshold (cardiovascular disease) | Transfuse if hemoglobin less than 8 g/dL; target 8-10 g/dL | Higher threshold for patients with acute coronary syndrome, symptomatic anemia, or active cardiac ischemia |
| Hemoglobin in variceal bleeding | Target 7-8 g/dL; avoid over-transfusion | Over-transfusion increases portal pressure and may worsen variceal bleeding |
| Blood pressure target | Mean arterial pressure greater than 65 mmHg | Maintain organ perfusion while avoiding excessive volume that may worsen bleeding |
| INR correction (if elevated) | Correct if INR greater than 2.5 and active bleeding; target INR less than 2.5 | Use prothrombin complex concentrate (faster) or fresh frozen plasma; vitamin K for sustained reversal |
| Platelet transfusion | Transfuse if platelet count less than 50,000/μL and active bleeding | Higher threshold (less than 50,000) for procedures or active hemorrhage |
Critical Concept: Restrictive Transfusion Strategy
Multiple randomized trials have demonstrated that a restrictive transfusion strategy (hemoglobin threshold 7 g/dL) improves outcomes compared to liberal transfusion (threshold 9 g/dL) in upper gastrointestinal bleeding:
- Lower 45-day mortality
- Reduced rebleeding rates
- Fewer complications (especially in variceal bleeding where over-transfusion increases portal pressure)
Exception: Consider higher threshold (8 g/dL) in patients with acute coronary syndrome or symptomatic cardiovascular disease.
Step 3: Variceal vs Non-Variceal Pathway
Suspected Variceal Bleeding
Clinical clues: Known cirrhosis, stigmata of liver disease, history of varices, massive painless hematemesis
- Start vasoactive therapy immediately (octreotide or terlipressin)
- Prophylactic antibiotics (ceftriaxone 1g IV daily × 7 days)
- Restrictive transfusion (target hemoglobin 7-8 g/dL)
- Urgent endoscopy within 12 hours with band ligation
- If refractory: Consider balloon tamponade as bridge to TIPS or surgery
- Secondary prophylaxis: Non-selective beta-blocker + band ligation program
Suspected Non-Variceal Bleeding
Clinical clues: NSAID use, dyspepsia history, no liver disease, coffee-ground emesis
- IV proton pump inhibitor (high-dose if high-risk features)
- Risk stratify with Glasgow-Blatchford score
- Endoscopy within 24 hours (within 12 hours if high-risk)
- Endoscopic therapy for high-risk stigmata (Forrest Ia, Ib, IIa, IIb)
- Post-endoscopy: Continue proton pump inhibitor, test for Helicobacter pylori
- Discontinue culprit medications (NSAIDs, aspirin if possible)
Step 4: Proton Pump Inhibitor Strategy
| Clinical Scenario | Proton Pump Inhibitor Regimen | Rationale |
|---|---|---|
| Pre-endoscopy (all patients) | IV proton pump inhibitor bolus (pantoprazole 80 mg or equivalent) | May downstage lesions; does not replace need for endoscopy |
| High-risk stigmata post-endoscopy (Forrest Ia, Ib, IIa, IIb) | IV proton pump inhibitor 80 mg bolus then 8 mg/hour continuous infusion × 72 hours | Maintains gastric pH greater than 6; reduces rebleeding by 40-50% |
| Low-risk stigmata post-endoscopy (Forrest IIc, III) | Oral proton pump inhibitor twice daily | High-dose infusion not required; can transition to oral therapy |
| After 72-hour infusion | Transition to oral proton pump inhibitor twice daily × 2 weeks, then once daily | Promotes ulcer healing; continue until Helicobacter pylori eradicated and NSAIDs stopped |
Step 5: Post-Endoscopy Management Decisions
| Endoscopic Finding | Disposition | Monitoring | Follow-up |
|---|---|---|---|
| High-risk stigmata (Forrest Ia, Ib, IIa) | ICU or step-down unit × 24-48 hours minimum | Serial hemoglobin every 6-8 hours, continuous telemetry, strict NPO initially | Repeat endoscopy only if clinical evidence of rebleeding |
| Intermediate-risk (Forrest IIb after clot removal) | Monitored bed × 24-48 hours | Serial hemoglobin every 8-12 hours | Advance diet as tolerated; repeat endoscopy if rebleeding |
| Low-risk stigmata (Forrest IIc, III) | Regular nursing floor; consider early discharge (24-48 hours) | Hemoglobin at 24 hours if stable | Outpatient follow-up; ensure Helicobacter pylori testing and treatment |
| Variceal bleeding after successful banding | ICU × 24-48 hours | Complete vasoactive therapy (48-72 hours total), continue antibiotics | Repeat endoscopy in 1-2 weeks for repeat banding; start beta-blocker |
| Mallory-Weiss tear (no active bleeding) | Observation × 24 hours; early discharge if stable | Single hemoglobin check if stable | Antiemetics; outpatient follow-up |
Step 6: Managing Rebleeding
Signs of Rebleeding:
- Fresh hematemesis or new melena after initial stabilization
- Hemoglobin drop greater than 2 g/dL over 24 hours despite no other explanation
- Hemodynamic instability (new tachycardia, hypotension) after initial resuscitation
- Increasing transfusion requirements
| Scenario | Management Approach |
|---|---|
| First rebleed after endoscopic therapy | Repeat endoscopy with repeat endoscopic therapy (combination therapy: injection + thermal or mechanical) |
| Second rebleed or failed repeat endoscopy | Interventional radiology (transcatheter arterial embolization) or surgery |
| Variceal rebleeding after band ligation | Repeat endoscopy; if refractory, consider TIPS (transjugular intrahepatic portosystemic shunt) or balloon tamponade as bridge |
| Massive rebleeding with hemodynamic collapse | Resuscitate, emergent surgical consultation; balloon tamponade (Sengstaken-Blakemore or Minnesota tube) for variceal bleeding as temporizing measure |
Step 7: Anticoagulation and Antiplatelet Decision-Making
| Clinical Situation | Immediate Action | Long-term Consideration |
|---|---|---|
| Warfarin with supratherapeutic INR and major bleeding | Hold warfarin, IV vitamin K 10 mg, 4-factor prothrombin complex concentrate (or fresh frozen plasma if unavailable) | Reassess anticoagulation indication; consider lower target INR or alternative agent |
| Direct oral anticoagulant with major bleeding | Hold medication; specific reversal agent if available (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors); activated charcoal if recent ingestion | Resume after bleeding controlled and source treated; consider proton pump inhibitor co-prescription |
| Aspirin for primary prevention | Hold aspirin; discontinue permanently if bleeding from peptic ulcer | Reassess cardiovascular risk; primary prevention rarely outweighs bleeding risk after gastrointestinal hemorrhage |
| Aspirin for secondary prevention (prior myocardial infarction or stroke) | Hold during active bleeding; resume as soon as hemostasis achieved (typically within 3-7 days) | Long-term proton pump inhibitor co-prescription mandatory; cardiology consultation |
| Dual antiplatelet therapy post-coronary stent | Discuss with interventional cardiology; risk of stent thrombosis versus bleeding; may continue aspirin and hold P2Y12 inhibitor briefly | Resume dual antiplatelet therapy as soon as feasible; add proton pump inhibitor permanently |
Troubleshooting: “What Do I Do If…”
Common Clinical Dilemmas
- Patient too unstable for endoscopy? — Focus on resuscitation first; intubate for airway protection if needed; consider angiography with embolization if cannot stabilize
- Endoscopy non-diagnostic but patient still bleeding? — Consider repeat endoscopy after aggressive gastric lavage, CT angiography, or tagged red blood cell scan
- Cannot stop anticoagulation (mechanical heart valve)? — Reverse acutely, achieve hemostasis, restart anticoagulation as soon as possible with hematology/cardiology guidance
- Patient refuses blood transfusion? — Document informed refusal, maximize medical management, consider erythropoietin and iron, early endoscopic intervention
- Suspected upper gastrointestinal bleeding but only hematochezia? — Place nasogastric tube; if bloody aspirate, proceed to upper endoscopy first; if clear, consider colonoscopy
- Elderly patient with multiple comorbidities and high surgical risk? — Maximize endoscopic and interventional radiology options; involve palliative care early if appropriate
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Initial hemoglobin is misleading: In acute hemorrhage, hemoglobin may be normal or near-normal initially due to proportional loss of red cells and plasma. It takes 24-72 hours for hemodilution to reveal the true extent of blood loss. Resuscitate based on clinical status, not initial hemoglobin.
Restrictive transfusion saves lives: Transfusing to a hemoglobin target of 7 g/dL (versus 9 g/dL) reduces mortality, rebleeding, and complications. Over-transfusion is particularly harmful in variceal bleeding as it increases portal pressure.
BUN:creatinine ratio helps localize bleeding: A ratio greater than 30:1 strongly suggests an upper gastrointestinal source due to absorption of blood proteins from the intestinal lumen. This can help when the source is unclear (e.g., patient with hematochezia).
Always consider aortoenteric fistula: Any patient with prior aortic surgery (open or endovascular) presenting with gastrointestinal bleeding must be evaluated for aortoenteric fistula. A “herald bleed” may precede catastrophic hemorrhage by hours to days.
Start vasoactive therapy empirically: In suspected variceal bleeding, start octreotide or terlipressin immediately upon presentation — do not wait for endoscopic confirmation. Early vasoactive therapy reduces mortality.
Antibiotics are essential in cirrhotic patients: All cirrhotic patients with gastrointestinal bleeding should receive prophylactic antibiotics (ceftriaxone) regardless of whether infection is suspected. This reduces bacterial infections, rebleeding, and mortality.
Test everyone with peptic ulcer for Helicobacter pylori: Helicobacter pylori eradication reduces ulcer recurrence from 60-80% to less than 5%. Test all patients with peptic ulcer bleeding and treat if positive. If initial test is negative, retest after acute illness resolves.
Glasgow-Blatchford score of 0-1 identifies very low-risk patients: These patients may be safely managed as outpatients with early outpatient endoscopy, avoiding unnecessary hospital admissions.
Critical Pitfalls to Avoid
Relying on normal vital signs: Young, healthy patients can maintain normal blood pressure until they have lost more than 30% of their blood volume. Tachycardia may be the only early sign, and beta-blockers can mask even that. Always consider the clinical context.
Attributing hematochezia to a lower source without evaluation: Massive upper gastrointestinal bleeding can present with bright red blood per rectum due to rapid intestinal transit. Always consider upper endoscopy or nasogastric lavage in patients with hematochezia and hemodynamic instability.
Delaying endoscopy for “stabilization”: While adequate resuscitation is important, prolonged delays in endoscopy (beyond 24 hours) are associated with worse outcomes. Endoscopy can be both diagnostic and therapeutic — it is part of the treatment, not just a diagnostic test.
Over-transfusing patients with variceal bleeding: Liberal transfusion in variceal bleeding increases portal pressure and worsens bleeding. Target hemoglobin 7-8 g/dL and avoid over-resuscitation with crystalloids as well.
Forgetting to stop NSAIDs: Patients often resume NSAIDs after discharge, leading to recurrent bleeding. Clearly document the need to avoid NSAIDs, provide alternatives for pain management, and communicate with the primary care physician.
Assuming negative Helicobacter pylori test is definitive: Acute bleeding, recent proton pump inhibitor use, and antibiotics all reduce sensitivity of Helicobacter pylori testing. If initial tests are negative but clinical suspicion is high, retest 4-8 weeks later off proton pump inhibitors.
Permanently stopping antiplatelet therapy after bleeding: In patients taking aspirin for secondary cardiovascular prevention, the risk of cardiovascular events from stopping aspirin often exceeds the risk of rebleeding. Resume as soon as hemostasis is achieved (typically 3-7 days) with proton pump inhibitor co-prescription.
Missing the “herald bleed” of aortoenteric fistula: A small gastrointestinal bleed in a patient with prior aortic surgery may be the warning sign of impending catastrophic hemorrhage. Always obtain CT angiography and involve vascular surgery early.
Key Takeaways
- Upper gastrointestinal bleeding is defined as hemorrhage proximal to the ligament of Treitz and presents as hematemesis, coffee-ground emesis, melena, or (in massive bleeding) hematochezia.
- The “Big Four” causes of non-variceal upper gastrointestinal bleeding are peptic ulcer disease, erosive disease, Mallory-Weiss tears, and malignancy — together accounting for more than 90% of cases.
- Initial hemoglobin does not reflect the severity of acute blood loss; clinical assessment of hemodynamic status and serial measurements are essential.
- Use a restrictive transfusion strategy (hemoglobin threshold 7 g/dL) — this improves outcomes compared to liberal transfusion, especially in variceal bleeding.
- The Glasgow-Blatchford score is the best pre-endoscopic risk stratification tool; a score of 0-1 identifies patients who may be safely managed as outpatients.
- Esophagogastroduodenoscopy should be performed within 24 hours for most patients, within 12 hours for high-risk patients, and emergently for massive hemorrhage unresponsive to resuscitation.
- In suspected variceal bleeding, start vasoactive therapy (octreotide or terlipressin) and prophylactic antibiotics immediately — do not wait for endoscopic confirmation.
- High-dose proton pump inhibitor infusion (80 mg bolus then 8 mg/hour × 72 hours) after endoscopic therapy for high-risk ulcers reduces rebleeding by maintaining gastric pH above 6.
- All patients with peptic ulcer bleeding must be tested for Helicobacter pylori infection and treated if positive — this dramatically reduces recurrence.
- Any patient with prior aortic surgery presenting with gastrointestinal bleeding must be evaluated for aortoenteric fistula — this is a surgical emergency with near-100% mortality if missed.
Quick Reference Algorithm
Systematic Approach to Upper Gastrointestinal Bleeding:
- Assess and resuscitate: Two large-bore IVs, crystalloid resuscitation, type and crossmatch, assess hemodynamic status
- Risk stratify: Calculate Glasgow-Blatchford score; determine disposition and endoscopy timing
- Determine likely etiology: Variceal (cirrhosis, liver disease) versus non-variceal (NSAID use, dyspepsia)
- Initiate targeted therapy: Proton pump inhibitor for all; add vasoactive therapy and antibiotics if variceal suspected
- Perform endoscopy: Within 24 hours (most patients) or 12 hours (high-risk); provide endoscopic therapy as indicated
- Post-endoscopy care: Continue proton pump inhibitor; monitor for rebleeding; test for Helicobacter pylori
- Address underlying cause: Eradicate Helicobacter pylori, stop NSAIDs, manage anticoagulation, arrange secondary prophylaxis for varices
- Plan follow-up: Ensure outpatient follow-up, medication reconciliation, and repeat endoscopy if indicated